RE:ProMIS initiates commercialization of COVID-19 assayGreat news!
Interesting that there is no mention of Immusafe here. If I recall, Immusafe is targeting the market for "physicians and their patients." Per the COVID immunity passport website.
COVID immunity passport dot com appears to be targeting the general public.
This new PR indicates ProMIS is directly targeting the government sector and large organizations.
It will be interesting to learn how each of these three revenue streams is split between PMN and BCNI and what the size of each market will be. We know the Immusafe JV is 50-50, and due to insurance coverage, I suspect that will be the largest market.
The total picture is still developing here. My guess is this PR was triggered by the hiring of the new executive being a material event.
But things are looking very good!